CO-AMP-ROBOTICS-CORP
19.7.2021 10:02:11 CEST | Business Wire | Press release
AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, is expanding its presence in Europe as demand grows for the company’s AI and automation solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210719005207/en/
AMP has appointed REP-TEC Advanced Technologies , specialists in the supply, installation, and support of recycling equipment, as an official reseller and integrator for customers in the United Kingdom and Ireland. In addition, to further support the expansion of its business in Europe, AMP has hired Gary Ashburner as its European General Manager to build out the company’s infrastructure across the region. Based in the UK, Ashburner leads customer and partner acquisition, pre- and post-sales consulting, system design, supply, installation, training, and service.
“We’re seeing greater interest in and adoption of our technology in the U.S., with customers reordering our AI-guided robotic sorting systems to install in other facilities that they own. This is generating a robust pipeline in the U.S. that’s being mirrored internationally, following the installation of our first robotic sorting system in Europe late last year,” said Ashburner. “We share a commitment to improving global resource efficiency and productivity with REP-TEC, and look forward to working with an established leader that also embraces new technology and innovation as we extend our efforts to modernize and expand recycling infrastructure in Europe and globally.”
AMP’s European expansion reflects strong year-over-year revenue growth and investment in operational scale made possible by its latest funding round of USD $55 million at the beginning of the year. The company’s AI platform, AMP Neuron™, encompasses the largest known real-world dataset of recyclable materials for machine learning , with the ability to classify more than 100 different categories and characteristics of recyclables across single-stream recycling, e-scrap, and construction and demolition debris, and reaching an object recognition run rate of more than 10 billion items annually.
“We’re delighted to partner with AMP Robotics and support the company’s growth across the UK and Ireland,” said Colm Grimes, CEO of REP-TEC. “We recognize the desire to add AI and robotics to Europe’s recycling infrastructure and believe AMP has developed a system that will change the economics of this industry. We’ll be installing our first three AMP Cortex™ high-speed sorting systems later this summer. This will provide a great UK reference site with the ability to run material trials for interested parties.”
To further its market penetration, AMP is actively seeking to establish additional reseller partnerships in Belgium, The Netherlands, Luxembourg, Germany, and France.
About AMP Robotics™ Corp.
AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, and high-value materials from construction and demolition debris.
About REP-TEC
REP-TEC was formed with a vision to improve global resource efficiency through automation and harnessing new waste recycling technologies. REP-TEC are specialists in the design, manufacture, installation, and support of a range of recycling solutions. The REP-TEC portfolio includes fully automatic balers, conveyor systems, compactors, and the AMP Cortex™ high-speed robotics systems. REP-TEC is passionate about innovation and exploring clients’ workstreams to uncover opportunities for significant efficiency improvements. With coverage throughout the UK and Ireland, REP-TEC provides nationwide aftersales service and support that meets the most demanding Service Level Agreements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005207/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom